Research ArticleArticle
Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study
Hasan Gökcer Tekin, Jashin J. Wu, Russel Burge, Julie Birt and Alexander Egeberg
The Journal of Rheumatology March 2019, jrheum.180670; DOI: https://doi.org/10.3899/jrheum.180670
Hasan Gökcer Tekin
From the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, California; Eli Lilly and Co., Indianapolis, Indiana; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, Ohio, USA. This study was funded by Eli Lilly and Co. The funding source participated in interpretation of the final analyzed study results, but had no access to the raw data, and did not participate in data collection, management, or analysis. Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr. Burge and J. Birt are currently employed by Eli Lilly and Co. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. H.G. Tekin, MD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen; J.J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology; R. Burge, PhD, Eli Lilly and Co., and Division of Pharmaceutical Sciences, University of Cincinnati; J. Birt, PharmD, Eli Lilly and Co.; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen. Address correspondence to Dr. A. Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark. E-mail: alexander.egeberg@gmail.com. Accepted for publication October 23, 2018.
Jashin J. Wu
From the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, California; Eli Lilly and Co., Indianapolis, Indiana; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, Ohio, USA. This study was funded by Eli Lilly and Co. The funding source participated in interpretation of the final analyzed study results, but had no access to the raw data, and did not participate in data collection, management, or analysis. Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr. Burge and J. Birt are currently employed by Eli Lilly and Co. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. H.G. Tekin, MD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen; J.J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology; R. Burge, PhD, Eli Lilly and Co., and Division of Pharmaceutical Sciences, University of Cincinnati; J. Birt, PharmD, Eli Lilly and Co.; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen. Address correspondence to Dr. A. Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark. E-mail: alexander.egeberg@gmail.com. Accepted for publication October 23, 2018.
Russel Burge
From the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, California; Eli Lilly and Co., Indianapolis, Indiana; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, Ohio, USA. This study was funded by Eli Lilly and Co. The funding source participated in interpretation of the final analyzed study results, but had no access to the raw data, and did not participate in data collection, management, or analysis. Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr. Burge and J. Birt are currently employed by Eli Lilly and Co. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. H.G. Tekin, MD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen; J.J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology; R. Burge, PhD, Eli Lilly and Co., and Division of Pharmaceutical Sciences, University of Cincinnati; J. Birt, PharmD, Eli Lilly and Co.; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen. Address correspondence to Dr. A. Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark. E-mail: alexander.egeberg@gmail.com. Accepted for publication October 23, 2018.
Julie Birt
From the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, California; Eli Lilly and Co., Indianapolis, Indiana; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, Ohio, USA. This study was funded by Eli Lilly and Co. The funding source participated in interpretation of the final analyzed study results, but had no access to the raw data, and did not participate in data collection, management, or analysis. Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr. Burge and J. Birt are currently employed by Eli Lilly and Co. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. H.G. Tekin, MD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen; J.J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology; R. Burge, PhD, Eli Lilly and Co., and Division of Pharmaceutical Sciences, University of Cincinnati; J. Birt, PharmD, Eli Lilly and Co.; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen. Address correspondence to Dr. A. Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark. E-mail: alexander.egeberg@gmail.com. Accepted for publication October 23, 2018.
Alexander Egeberg
From the Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, California; Eli Lilly and Co., Indianapolis, Indiana; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, Ohio, USA. This study was funded by Eli Lilly and Co. The funding source participated in interpretation of the final analyzed study results, but had no access to the raw data, and did not participate in data collection, management, or analysis. Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr. Burge and J. Birt are currently employed by Eli Lilly and Co. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. H.G. Tekin, MD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen; J.J. Wu, MD, Kaiser Permanente Los Angeles Medical Center, Department of Dermatology; R. Burge, PhD, Eli Lilly and Co., and Division of Pharmaceutical Sciences, University of Cincinnati; J. Birt, PharmD, Eli Lilly and Co.; A. Egeberg, MD, PhD, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen. Address correspondence to Dr. A. Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark. E-mail: alexander.egeberg@gmail.com. Accepted for publication October 23, 2018.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study
Hasan Gökcer Tekin, Jashin J. Wu, Russel Burge, Julie Birt, Alexander Egeberg
The Journal of Rheumatology Mar 2019, jrheum.180670; DOI: 10.3899/jrheum.180670